LGALS9 and nasopharyngeal carcinoma: Indeed, we have previously described that antagonizing only human LGALS9 with a specific monoclonal antibody is sufficient to both neutralize human Treg suppressive activity and induce a strong anti-tumor immune response in a humanized mouse model of NPC also known to express high level of LGALS9 (58).